65,437 trials
Influenza
Primary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 89.7; 80.0; 89.7; 71.7 Percentage of participants
Smoking
Primary: Number of Participants Not Smoking in the Previous 7 Days, Confirmed by Expired Carbon Monoxide Reading < 10 Parts Per Million at Week 52 — 10; 11 participants
Hernia
Primary: Hernia Recurrence Rate of Hernias Post Repair With Sepramesh. — 1 participants
Skin Cancer
Primary: Number of Days the Subjects Are Adherent to Using Sunscreen — 12.6; 23.6 days
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Progression Free Rate at 4 Months — 8; 7 Participants
Drug Addiction · Smoking Cessation
Primary: Subjective Effects — 18.8; 23.1; 25.6; 24.2 units on a scale
Leukemia, Acute Myeloid · Myelodysplastic Syndrome
Primary: Clinical Response at the End of Temozolomide Induction — 10; 2; 4; 8 participants
Erythema Chronicum Migrans
Primary: Objective Sequelae and Post-treatment Subjective New or Increased Symptoms (NOIS)in Patients Treated for Erythema Migrans With Doxycycline for 10 or 15 Days. — 79; 85…
Neoplasms, Breast
Primary: Number of Participants With Overall Response (OR), Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR), Assessed Per Response…
Neck Pain
Primary: Pain on Movement — 19.5; 56.9 mm
HIV Infection
Primary: Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells) — 2.2; -0.7…
Thrombosis, Venous
Primary: Number of Participants With Venous Thromboembolism (VTE) or Death up to the Time of Complete Mobilization — 48; 15 participants — p=<0.001
Bipolar Depression
Primary: The 25-Item Hamilton Depression Rating Scale. — 23.3; 22.1; 17.5; 18.5 units on a scale
Diabetes Mellitus, Type 2
Primary: Frequency of Patients With Adverse Events (AEs) — 124; 149; 132; 4 participant
Metastatic Breast Cancer
Primary: Percentage of Participants With Objective Response (OR; Assessed by Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1) — 60.0; 52.0 percentage of…